Investors & News / Exelixis Announces Initiation of the STELLAR-305 Phase 2/3 Pivotal Trial Evaluating Zanzalintinib in Combination with Pembrolizumab in Patients with Previously Untreated Recurrent or Metastatic Head and Neck Cancer Read more about Exelixis Announces Initiation of the STELLAR-305 Phase 2/3 Pivotal Trial Evaluating Zanzalintinib in Combination with Pembrolizumab in Patients with Previously Untreated Recurrent or Metastatic Head and Neck Cancer Exelixis and Arcus Biosciences Announce Clinical Trial Collaboration to Evaluate Zanzalintinib in Combination with AB521 in Patients with Advanced Renal Cell Carcinoma Read more about Exelixis and Arcus Biosciences Announce Clinical Trial Collaboration to Evaluate Zanzalintinib in Combination with AB521 in Patients with Advanced Renal Cell Carcinoma Exelixis to Present at the Piper Sandler 35th Annual Healthcare Conference on November 28, 2023 Read more about Exelixis to Present at the Piper Sandler 35th Annual Healthcare Conference on November 28, 2023 Exelixis Announces Encouraging Results from Expansion Cohort of Phase 1b STELLAR-001 Trial Evaluating Zanzalintinib in Patients with Advanced Kidney Cancer at IKCS 2023 Read more about Exelixis Announces Encouraging Results from Expansion Cohort of Phase 1b STELLAR-001 Trial Evaluating Zanzalintinib in Patients with Advanced Kidney Cancer at IKCS 2023 Exelixis Announces Third Quarter 2023 Financial Results and Provides Corporate Update Read more about Exelixis Announces Third Quarter 2023 Financial Results and Provides Corporate Update Detailed Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2023 Read more about Detailed Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2023 Exelixis to Release Third Quarter 2023 Financial Results on Wednesday, November 1, 2023 Read more about Exelixis to Release Third Quarter 2023 Financial Results on Wednesday, November 1, 2023 Robert Burns Robert Burns H.C. Wainwright Exelixis and Insilico Medicine Enter into Exclusive Global License Agreement for ISM3091, a Potentially Best-in-Class USP1 Inhibitor Read more about Exelixis and Insilico Medicine Enter into Exclusive Global License Agreement for ISM3091, a Potentially Best-in-Class USP1 Inhibitor Exelixis to Webcast Fireside Chats as Part of Investor Conferences in September Read more about Exelixis to Webcast Fireside Chats as Part of Investor Conferences in September Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page Next › Last page Last » Subscribe to Receive Email Alerts Sign up to receive email alerts whenever Exelixis, Inc. posts new information to the site. Just enter your email address and click Sign Up. Required fields denoted by an asterisk (). Alert type Exelixis SEC Alert Exelixis End-of-Day SEC Alert Exelixis Calendar Alert Exelixis News Alert Exelixis Report Alert Email Leave this field blank Shareholder Tools Information Request Print Page RSS
Exelixis Announces Initiation of the STELLAR-305 Phase 2/3 Pivotal Trial Evaluating Zanzalintinib in Combination with Pembrolizumab in Patients with Previously Untreated Recurrent or Metastatic Head and Neck Cancer Read more about Exelixis Announces Initiation of the STELLAR-305 Phase 2/3 Pivotal Trial Evaluating Zanzalintinib in Combination with Pembrolizumab in Patients with Previously Untreated Recurrent or Metastatic Head and Neck Cancer
Exelixis and Arcus Biosciences Announce Clinical Trial Collaboration to Evaluate Zanzalintinib in Combination with AB521 in Patients with Advanced Renal Cell Carcinoma Read more about Exelixis and Arcus Biosciences Announce Clinical Trial Collaboration to Evaluate Zanzalintinib in Combination with AB521 in Patients with Advanced Renal Cell Carcinoma
Exelixis to Present at the Piper Sandler 35th Annual Healthcare Conference on November 28, 2023 Read more about Exelixis to Present at the Piper Sandler 35th Annual Healthcare Conference on November 28, 2023
Exelixis Announces Encouraging Results from Expansion Cohort of Phase 1b STELLAR-001 Trial Evaluating Zanzalintinib in Patients with Advanced Kidney Cancer at IKCS 2023 Read more about Exelixis Announces Encouraging Results from Expansion Cohort of Phase 1b STELLAR-001 Trial Evaluating Zanzalintinib in Patients with Advanced Kidney Cancer at IKCS 2023
Exelixis Announces Third Quarter 2023 Financial Results and Provides Corporate Update Read more about Exelixis Announces Third Quarter 2023 Financial Results and Provides Corporate Update
Detailed Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2023 Read more about Detailed Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2023
Exelixis to Release Third Quarter 2023 Financial Results on Wednesday, November 1, 2023 Read more about Exelixis to Release Third Quarter 2023 Financial Results on Wednesday, November 1, 2023
Exelixis and Insilico Medicine Enter into Exclusive Global License Agreement for ISM3091, a Potentially Best-in-Class USP1 Inhibitor Read more about Exelixis and Insilico Medicine Enter into Exclusive Global License Agreement for ISM3091, a Potentially Best-in-Class USP1 Inhibitor
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in September Read more about Exelixis to Webcast Fireside Chats as Part of Investor Conferences in September
